Cell Cryopreservation Market to reach USD 90.92 Billion by 2035 at 19.8% CAGR

The global cell cryopreservation market is projected to grow from USD 17.89 billion in 2026 to USD 90.92 billion by 2035, according to Market Research Future. This growth represents a compound annual growth rate (CAGR) of 19.8%, driven by the commercial scale-up of cell and gene therapy (CGT) and the expansion of government-backed biobanks.

Market Research Future estimated the market base at USD 14.93 billion in 2025. The report attributes the expansion to three primary forces: the need for validated cryogenic storage across CGT supply chains, massive government investments in biological sample infrastructure, and a shift toward automated, closed-system storage platforms.

Why is the cell cryopreservation market expanding?

The commercialization of cell and gene therapies is the primary growth driver. Market Research Future reports that by mid-2025, more than 1,900 active clinical trials existed in the global CGT pipeline, with the FDA approving over 20 novel therapies between 2022 and 2024.

Every approved CGT product requires validated cryogenic storage at multiple points, including manufacturing suites, apheresis centers, and points of care. This creates recurring demand for equipment and consumables.

Government initiatives are also fueling growth. China’s National Biobank Network planned an investment of over USD 850 million between 2024 and 2028 to establish 15 regional tissue repositories. In the U.S., the NIH All of Us Research Program has over 300,000 enrollees, resulting in hundreds of millions of dollars in sample storage contracts.

Did You Know? Social egg freezing in OECD nations has grown by approximately 25% annually since 2020, supported in part by employer-sponsored fertility benefits from companies including Meta, Google, and Apple.

How is technology changing biological sample preservation?

Automated, closed-system platforms are replacing legacy manual freezing cabinets. Vitrification-based stem cell freezing technology now demonstrates post-thaw viability rates above 90%, which has led to its adoption over conventional slow-freeze protocols in regenerative-medicine labs and IVF clinics.

According to Market Research Future, machine-learning algorithms are now being used to optimize freeze-thaw protocols in real time. These systems adjust cryoprotectant concentrations and cooling rates based on specific cell-type viability data.

The equipment segment is the fastest-growing product category, with an estimated CAGR of 21.3%. However, a fully automated controlled-rate freezer can cost between USD 45,000 and USD 120,000 per unit, leading to the emergence of leasing and equipment-as-a-service models for smaller clinics.

Expert Insight: Samantha Carter notes that the shift toward GMP-certified, xeno-free media—driven by updated 2024 FDA guidance and 2025 EU regulations—creates a higher-margin product tier. This regulatory pressure forces a transition from research-grade materials to clinical-grade standards, fundamentally altering the cost structure for biopharmaceutical manufacturers.

Which regions and companies lead the market?

North America held the dominant market share at approximately 38% in 2025, with the U.S. generating about 78% of that regional revenue. Europe followed with a 27% share, totaling approximately USD 4.03 billion in 2025.

🚨 LEAKED Houston Texans 2026 Schedule, Opponents & Instant Analysis | NFL Schedule Release

The Asia-Pacific region is the fastest-growing area, with a CAGR of 22.4% between 2026 and 2035. India is growing at 24.8% CAGR, supported by the National Biopharma Mission’s target of 20 new biorepositories by 2028.

Thermo Fisher Scientific leads the competitive landscape, commanding 12% to 15% of global revenue. Merck KGaA holds 8% to 11%, while BioLife Solutions holds 7% to 10%. In June 2024, Thermo Fisher expanded its Gibco CTS cryopreservation media manufacturing in Grand Island, NY, increasing capacity by 40%.

What may happen next in cryopreservation?

By 2030, digital immunization registries may evolve into integrated biobank data platforms. The WHO targets near-universal adoption of digital registries by the early 2030s, which could increase biobank utilization rates through better sample tracking.

AI-powered bioprocess optimization may further reframe cost structures by the early 2030s. Predictive maintenance could reduce liquid-nitrogen storage tank failures, potentially expanding cryogenic storage from centralized biobanks to community fertility clinics and decentralized clinical trial sites.

Frequently Asked Questions

What is the projected value of the cell cryopreservation market by 2035?
According to Market Research Future, the market is expected to reach USD 90.92 billion by 2035.

What is the most dominant application for cell cryopreservation?
Stem cells are the dominant application, valued at roughly USD 5.52 billion in 2025.

How does vitrification impact the success of IVF clinics?
Vitrification pushes post-thaw survival rates beyond 95% in leading clinics, displacing older slow-freeze protocols.

How do you think the rise of employer-sponsored fertility benefits will impact healthcare accessibility in the coming decade?